A watchdog advisory panel, meeting at HMS, concluded Tuesday that a new class of powerful cholesterol-lowering drugs did not offer reasonable value to most patients given their high price tags. Jason Wasfy (Mass General) and Steven Pearson (Harvard Pilgrim Health Care) are quoted.
Trending News
Search for Babesiosis Treatment Gets a New Map
New clues to help fight tick-borne disease
Can an AI ‘Co-Scientist’ Accelerate Cancer Research?
Nearly $7 million funds agentic AI tools to assist investigations into cancer’s most pressing…
First Large-Scale Study Shows How Doctors Use AI in Medicine
Which practitioners use artificial intelligence in the clinic, and what do they ask?